1812. Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Skin Structure Infections in US Medical Centers between 2017–2019 and 2022

BACKGROUND: A new formulation of oritavancin (ORI) was developed and approved by the US FDA to be infused over 1 hour for the treatment of acute bacterial skin and skin structure infection (ABSSSI). The activity of ORI and comparators against Staphylococcus aureus (SA), β-hemolytic streptococci (BHS...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalhaes, Cecilia G, Mendes, Rodrigo E, Shortridge, Dee, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678100/
http://dx.doi.org/10.1093/ofid/ofad500.1641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678100/
http://dx.doi.org/10.1093/ofid/ofad500.1641

Ejemplares similares